ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -2 مورد

Acetylcysteine (N-acetylcysteine): Drug information

Acetylcysteine (N-acetylcysteine): Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Acetylcysteine (N-acetylcysteine): Patient drug information" and "Acetylcysteine (N-acetylcysteine): Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Acetadote
Brand Names: Canada
  • Parvolex [DSC]
Pharmacologic Category
  • Antidote;
  • Mucolytic Agent
Dosing: Adult
Acetaminophen overdose

Acetaminophen overdose: Note: Consultation with a poison center or clinical toxicologist is highly recommended to determine optimal patient care.

Initiation of therapy:

Acute acetaminophen ingestion when the time of ingestion and history is known: Treatment should begin as soon as the need becomes evident, preferably starting no later than 8 to 10 hours postingestion (Ref). The decision to initiate treatment following acute ingestion is based on patient history (eg, time of ingestion, the timing of presentation, dose, formulation, duration of ingestion, concomitant medications, comorbid conditions), physical exam (including signs or symptoms of liver injury), and the initial serum acetaminophen concentration. Ideally, the initial serum acetaminophen concentration should be drawn between 4 and 24 hours postingestion to determine if the patient is a candidate for acetylcysteine therapy. If the serum acetaminophen concentration will return >8 hours postingestion or if the ingestion was ≥30 grams, initiate acetylcysteine treatment immediately and continue until stopping criteria are met (Ref).

• Patients who present 0 to 4 hours postingestion: Obtain a serum acetaminophen concentration at 4 hours postingestion and plot on the revised Rumack-Matthew nomograph; initiate acetylcysteine treatment if the serum acetaminophen concentration falls on or above the treatment line and continue until stopping criteria are met. Patients with an undetectable serum acetaminophen concentration at 2 to 4 hours postingestion are unlikely to have ingested a significant amount of acetaminophen; however, consultation with a poison center or clinical toxicologist is recommended to determine the appropriate course of action (Ref).

• Patients who present 4 to 8 hours postingestion: Obtain a serum acetaminophen concentration immediately and plot on the revised Rumack-Matthew nomograph; initiate acetylcysteine treatment if the serum acetaminophen concentration falls on or above the treatment line and continue until stopping criteria are met (Ref).

• Patients who present 8 to 24 hours postingestion: Immediately initiate acetylcysteine therapy and obtain a serum acetaminophen concentration and complete metabolic panel; when the serum acetaminophen concentration results are available, plot on the revised Rumack-Matthew nomograph. If the serum acetaminophen concentration is on or above the treatment line, continue acetylcysteine therapy until stopping criteria are met; if the initial serum acetaminophen concentration is below the treatment line, discontinuation of acetylcysteine therapy may be considered (Ref).

• Patients who present >24 hours postingestion: Immediately initiate acetylcysteine therapy and obtain a serum acetaminophen concentration and complete metabolic panel. If the serum acetaminophen concentration is >10 mcg/mL or if serum transaminases are abnormal (unless the abnormality reflects baseline for that patient), continue acetylcysteine therapy until stopping criteria are met. If the serum acetaminophen concentration is ≤10 mcg/mL and serum transaminases are normal (unless abnormal is baseline for that patient), discontinuation of acetylcysteine therapy may be considered (Ref).

• Acute coingestion of acetaminophen and anticholinergic or opioid agonist medications: Obtain a serum acetaminophen concentration between 4 and 24 hours postingestion. Initiate treatment if the serum acetaminophen concentration, when plotted on the revised Rumack-Matthew nomograph, is on or above the treatment line; continue treatment until stopping criteria are met. If a serum acetaminophen concentration drawn between 4 and 24 hours is below the treatment line but >10 mcg/mL and the patient has concurrently taken agents that may delay acetaminophen absorption (eg anticholinergic or opioid agents), repeat the serum acetaminophen concentrations 4 to 6 hours after the first measurement to determine the need for acetylcysteine therapy (Ref).

• Acute ingestion of an extended-release acetaminophen product: Obtain a serum acetaminophen concentration between 4 and 24 hours postingestion. Initiate treatment if the serum acetaminophen concentration, when plotted on the revised Rumack-Matthew nomograph, is on or above the treatment line; continue treatment until stopping criteria are met. If a serum acetaminophen concentration drawn between 4 and 12 hours is below the treatment line but >10 mcg/mL, repeat the serum acetaminophen concentrations 4 to 6 hours after the first measurement to determine the need for acetylcysteine therapy (Ref).

Ingestion with an unknown or unreliable history: Obtain a serum acetaminophen concentration and complete metabolic panel. Immediately initiate acetylcysteine therapy (Ref). Alternatively, initiate acetylcysteine therapy if the serum acetaminophen concentration is >10 mcg/mL or if serum transaminases are abnormal (unless the abnormality reflects baseline for that patient). Continue treatment until stopping criteria are met (Ref).

Repeated supratherapeutic acetaminophen ingestion (RSTI): Obtain serum acetaminophen concentration, serum transaminases, and serum creatinine. Initiate acetylcysteine therapy if the serum acetaminophen concentration is ≥20 mcg/mL or if serum transaminases are abnormal (unless the abnormality reflects baseline for that patient); continue treatment until stopping criteria are met. Do not administer acetylcysteine if serum acetaminophen concentration is <20 mcg/mL and serum transaminases are normal (unless abnormal is baseline for that patient) (Ref).

Duration of therapy and stopping criteria: In patients who were deemed candidates for acetylcysteine therapy, treatment should continue for at least 20 to 24 hours (depending on the regimen chosen). Prior to the end of the infusion, measure the serum acetaminophen concentration, serum transaminases, and PT/INR; discontinue acetylcysteine therapy if the stopping criteria are met. If the stopping criteria are not met, continue acetylcysteine therapy and measure the serum acetaminophen concentration, serum transaminases, and PT/INR every 12 to 24 hours in addition to other clinical variables per institutional protocol (eg, factor V, presence of encephalopathy); once stopping criteria are met, treatment may be discontinued (Ref):

Stopping criteria:

• Serum acetaminophen concentration <10 mcg/mL

• INR <2

• Serum transaminases are normal for the patient or, if elevated, have decreased from the peak by 25% to 50%

• Patient is clinically well

Dosing regimen(s): Multiple regimens are available which may be country- and/or institution-specific; comparative efficacy has not been established. The chosen regimen should deliver at least 300 mg/kg orally or intravenously during the first 20 to 24 hours of treatment (Ref). Higher doses may be required following a high-risk ingestion (≥30 grams or a serum acetaminophen concentration that is on or above the high-risk line when plotted on the revised Rumack-Matthew nomograph) (Ref); consultation with a poison center or clinical toxicologist is highly recommended.

Labeled regimens and a select alternative regimen are provided below; refer to institution-specific regimen where applicable.

Oral (solution for oral administration):

72-hour regimen: Consists of 18 doses; total dose delivered: 1,330 mg/kg.

Loading dose: 140 mg/kg.

Maintenance dose: 70 mg/kg every 4 hours; repeat dose if emesis occurs within 1 hour of administration.

IV:

“Three-bag regimen” (21-hour regimen): Consists of 3 doses; total dose delivered: 300 mg/kg.

Loading dose: IV: 150 mg/kg (maximum: 15 g) infused over 1 hour.

Second dose: IV: 50 mg/kg (maximum: 5 g) infused over 4 hours.

Third dose: IV: 100 mg/kg (maximum: 10 g) infused over 16 hours.

Note: The “three-bag regimen” delivers a higher amount of acetylcysteine in the first 3 hours as compared to the “two-bag regimen” and may be preferred in patients with early signs of severe liver injury or a history of a large acetaminophen ingestion. The fluid volume should be reduced in patients weighing ≤40 kg. The IV route may be preferred in pregnant patients; however, there are no data to suggest the oral route would be less effective (Ref).

"Two-bag regimen" (20-hour regimen): Consists of 2 doses; total dose delivered: 300 mg/kg:

Loading dose: IV: 200 mg/kg (maximum: 20 g) infused over 4 hours.

Second dose: IV: 100 mg/kg (maximum: 10 g) infused over 16 hours.

Note: The manufacturer recommends use of the “two-bag regimen” in patients ≥41 kg; however, use in patients <41 kg has been described (Ref). The "two-bag regimen" delivers a lower amount of acetylcysteine over the first 3 hours and has been associated with fewer and milder nonimmune anaphylactic reactions as compared to the “three-bag regimen” (Ref).

Alternative recommendations: Refer to institution-specific regimen where applicable. The chosen regimen should deliver at least 300 mg/kg orally or intravenously during the first 20 to 24 hours of treatment (Ref).

"Single-bag regimen" (off-label dosing): Total dose delivered 430 mg/kg: IV: Initiate therapy with 150 mg/kg infused over 1 hour; then decrease the rate to 14 mg/kg/hour and infuse for an additional 20 hours (Ref).

Note: Patients weighing >69 kg will require a second bag to complete the dosing regimen.

Obesity: In patients who weigh >100 kg, the calculation of the IV acetylcysteine dose should be capped at 100 kg of body weight (Ref).

Adjuvant therapy in respiratory conditions

Adjuvant therapy in respiratory conditions:

Note: For inhaled/nebulized/direct instillation therapy, may consider premedication with an aerosolized bronchodilator 10 to 15 minutes prior to dose in patients with reactive airway disease or in patients who develop bronchospasm.

Inhalation, nebulization (face mask, mouth piece, tracheostomy): Acetylcysteine 10% and 20% solution (dilute 20% solution with sodium chloride or sterile water for inhalation); 10% solution may be used undiluted: 3 to 5 mL of 20% solution or 6 to 10 mL of 10% solution until nebulized given 3 to 4 times/day; dosing range: 1 to 10 mL of 20% solution or 2 to 20 mL of 10% solution every 2 to 6 hours.

Inhalation, nebulization (tent, croupette): Dose must be individualized; may require up to 300 mL solution/treatment.

Direct instillation:

Into tracheostomy: 1 to 2 mL of 10% to 20% solution every 1 to 4 hours.

Through percutaneous intratracheal catheter: 1 to 2 mL of 20% or 2 to 4 mL of 10% solution every 1 to 4 hours via syringe attached to catheter.

Diagnostic bronchogram

Diagnostic bronchogram: Note : For inhaled/nebulized/direct instillation therapy, may consider premedication with an aerosolized bronchodilator 10 to 15 minutes prior to dose in patients with reactive airway disease or in patients who develop bronchospasm.

Nebulization or intratracheal: 1 to 2 mL of 20% solution or 2 to 4 mL of 10% solution administered 2 to 3 times prior to procedure.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Seventy percent of total clearance is due to non–kidney-related mechanisms (Ref). However, a multiple-dose study of a sustained-release formulation of acetylcysteine in patients with end stage kidney disease demonstrated substantially reduced clearance (decreased by 90%), 7-fold larger AUC and 13-fold longer half-life compared with subjects with normal kidney function (Ref). However, acetylcysteine is generally well-tolerated and short courses of therapy can be considered without dose adjustment for kidney impairment (Ref).

Altered kidney function:

Oral, IV, inhalation: No dosage adjustment necessary for any degree of kidney dysfunction (Ref).

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2): Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (<55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

Oral, IV, inhalation: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly):

Oral, IV, inhalation: Dialyzable ~40% to 80% (Ref): No dosage adjustment necessary (Ref). Note: When administered as a continuous IV infusion for the treatment of acetaminophen overdose, double the acetylcysteine dose during the hemodialysis procedure to account for extracorporeal removal of the drug (Ref); consultation with a poison center or clinical toxicologist is highly recommended to determine optimal patient care.

Peritoneal dialysis: Oral, IV, inhalation: Likely to be dialyzable based on physicochemical characteristics: No dosage adjustment necessary (Ref).

CRRT: Oral, IV, inhalation: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral, IV, inhalation: No dosage adjustment necessary (Ref).

Dosing: Liver Impairment: Adult

Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Obesity: Adult

Refer to indication-specific dosing for obesity-related information (may not be available for all indications).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Acetylcysteine (N-acetylcysteine): Pediatric drug information")

Acetaminophen overdose

Acetaminophen overdose:

Note: Consultation with a poison control center or clinical toxicologist is highly recommended to determine optimal patient care.

Initiation of therapy:

Acute ingestion of immediate-release acetaminophen product: Treatment should begin as soon as the need becomes evident, preferably starting no later than 8 to 10 hours postingestion (Ref). The decision to initiate treatment following acute ingestion is dependent on the timing of presentation postingestion if known, the timing of serum acetaminophen concentration draw and expected time of results, the presence of signs or symptoms of liver injury, and the dose and formulation ingested. Initial serum acetaminophen concentration should be drawn ≥4 to 24 hours postingestion to determine if the patient is a candidate for acetylcysteine therapy. If the serum acetaminophen concentration will return >8 hours postingestion or if the ingestion was ≥500 mg/kg or ≥30 grams (whichever is less), initiate acetylcysteine treatment immediately and continue until stopping criteria are met (Ref).

• Patients who present 0 to 4 hours postingestion: Obtain a serum acetaminophen concentration at 4 hours postingestion and plot on the revised Rumack-Matthew nomogram; initiate acetylcysteine treatment if the serum acetaminophen concentration falls above the treatment line and continue until stopping criteria are met (Ref).

• Patients who present 4 to 8 hours postingestion:Obtain a serum acetaminophen concentration immediately and plot on the revised Rumack-Matthew nomogram; initiate acetylcysteine treatment if the serum acetaminophen concentration falls on or above the treatment line and continue until stopping criteria are met (Ref).

• Patients who present 8 to 24 hours postingestion: Immediately initiate acetylcysteine therapy and obtain a serum acetaminophen concentration and complete metabolic panel; when the serum acetaminophen concentration results are available, plot on the revised Rumack-Matthew nomogram. If the serum acetaminophen concentration is on or above the treatment line, continue acetylcysteine therapy until stopping criteria are met; if the initial serum acetaminophen concentration is below the treatment line, discontinuation of acetylcysteine therapy may be considered (Ref).

• Patients who present >24 hours postingestion:Immediately initiate acetylcysteine therapy and obtain a serum acetaminophen concentration and complete metabolic panel. If the serum acetaminophen concentration is >10 mcg/mL or if AST/ALT is abnormal (unless the abnormality reflects baseline for that patient), continue acetylcysteine therapy until stopping criteria are met. If the serum acetaminophen concentration is ≤10 mcg/mL and serum transaminases are normal (unless abnormal is baseline for patient), discontinuation of acetylcysteine therapy may be considered (Ref).

• Patients with unknown or unreliable history: Obtain a serum acetaminophen concentration and complete metabolic panel. Initiate acetylcysteine therapy if the serum acetaminophen concentration is >10 mcg/mL or if serum transaminases are abnormal (unless the abnormality reflects baseline for patient); treatment should continue until stopping criteria are met (Ref). Do not administer acetylcysteine if serum acetaminophen concentration is ≤10 mcg/mL and serum transaminases are normal (unless abnormal is baseline for patient) (Ref).

• Acute coingestion of acetaminophen and anticholinergic or opioid agonist medications: Obtain a serum acetaminophen concentration ≥4 to 24 hours postingestion. Initiate treatment if the serum acetaminophen concentration, when plotted on the revised Rumack-Matthew nomogram, is on or above the treatment line; treatment should continue until stopping criteria are met (Ref). If a serum acetaminophen concentration drawn between 4 and 24 hours is below the treatment line but >10 mcg/mL and the patient has concurrently taken agents that may delay acetaminophen absorption (eg, anticholinergic or opioid agents), repeat the serum acetaminophen concentrations 4 to 6 hours after the first measurement to determine the need for acetylcysteine therapy (Ref).

Acute ingestion of an extended-release acetaminophen product: Obtain a serum acetaminophen concentration ≥4 to 24 hours postingestion. Initiate treatment if the serum acetaminophen concentration, when plotted on the revised Rumack-Matthew nomogram, is on or above the treatment line; treatment should continue until stopping criteria are met. If a serum acetaminophen concentration drawn between 4 and 12 hours is below the treatment line but >10 mcg/mL, repeat the serum acetaminophen concentrations 4 to 6 hours after the first measurement to determine the need for acetylcysteine therapy (Ref).

Repeated supratherapeutic acetaminophen ingestion (RSTI): Obtain a serum acetaminophen concentration, serum transaminases, and serum creatinine. Initiate acetylcysteine therapy if the serum acetaminophen concentration is ≥20 mcg/mL or if serum transaminases are abnormal (unless the abnormality reflects baseline for patient); treatment should continue until stopping criteria are met. Do not administer acetylcysteine if serum acetaminophen concentration is <20 mcg/mL and serum transaminases are normal (unless abnormal is baseline for patient) (Ref).

Duration of therapy and stopping criteria: In patients who were deemed candidates for acetylcysteine therapy, treatment should continue for 20 to 24 hours (depending on the regimen chosen). Prior to end of infusion, assess the serum acetaminophen concentration, serum transaminases, and PT/INR; discontinue acetylcysteine therapy if the stopping criteria are met. If the stopping criteria are not met, continue acetylcysteine therapy and measure the serum acetaminophen concentration, serum transaminases, and PT/INR every 12 to 24 hours in addition to other clinical monitoring per institutional protocol; once stopping criteria are met, treatment may be discontinued (Ref):

Stopping criteria:

• Serum acetaminophen concentration <10 mcg/mL.

• INR <2.

• Serum transaminases are normal for the patient or, if elevated, have decreased from the peak by 25% to 50%.

• Patient is clinically well.

Dosing regimen(s): Multiple regimens are available which may be country- and/or institution-specific; comparative efficacy has not been established. The chosen regimen should deliver at least 300 mg/kg orally or IV during the first 20 to 24 hours of treatment. Higher doses may be required following a high-risk ingestion (≥500 mg/kg or ≥30 grams [whichever is less] or a serum acetaminophen concentration that is on or above the high-risk line when plotted on the revised Rumack-Matthew nomogram). Consultation with a poison control center or clinical toxicologist is highly recommended especially for high-risk ingestions and in patients <6 years of age who receive a single IV dose of acetaminophen >90 mg/kg or a cumulative IV dose >150 mg/kg over 24 hours (Ref).

Oral (solution for oral administration):

Note: There are no data for use of the OTC supplement tablets for acetaminophen poisoning.

Infants, Children, and Adolescents:

72-hour regimen: Consists of 18 doses; total dose delivered: 1,330 mg/kg.

Loading dose: Oral: 140 mg/kg; maximum dose: 15 g/dose.

Maintenance dose: Oral: 70 mg/kg every 4 hours for 17 doses starting 4 hours after loading dose; maximum dose: 7.5 g/dose; repeat dose if emesis occurs within 1 hour of administration. Note: Although not FDA approved, some experts may recommend a shortened course (<72 hours of treatment) or extended course of oral acetylcysteine therapy based on stopping criteria (Ref).

IV: Acetadote: Note: Dosing regimens vary and have not been directly compared; experts do not recommend one regimen over another, but only recommend a regimen that provides a total dose of 300 mg/kg during the first 20 to 24 hours (Ref). Administration beyond 20 or 21 hours may be necessary based on clinical scenario if stopping criteria are not met (Ref).

Three-bag method:

Infants, Children, and Adolescents: Limited data available in patients <5 kg:

21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg; maximum total dose: 30 g (Ref).

Loading dose: IV: 150 mg/kg infused over 60 minutes; maximum dose: 15 g/dose.

Second dose: IV: 50 mg/kg infused over 4 hours; maximum dose: 5 g/dose.

Third dose: IV: 100 mg/kg infused over 16 hours; maximum dose: 10 g/dose.

Two-bag method:

Infants, Children, and Adolescents: Limited data available in patients <41 kg: Note: Although not FDA approved in patients <41 kg, the "two-bag method" is safe and reduces adverse reactions and administration errors (Ref).

20-hour regimen: Consists of 2 doses; total dose delivered: 300 mg/kg; maximum total dose: 30 g (Ref).

First dose: IV: 200 mg/kg infused over 4 hours; maximum dose: 20 g/dose.

Second dose: IV: 100 mg/kg infused over 16 hours; maximum dose: 10 g/dose.

Respiratory conditions, adjuvant therapy

Respiratory conditions, adjuvant therapy: Note: Patients should receive an aerosolized bronchodilator 10 to 15 minutes prior to acetylcysteine:

Nebulized inhalation: Infants, Children, and Adolescents:

Face mask, mouthpiece, tracheostomy:

10% solution: Inhalation: Usual dose: 6 to 10 mL of 10% solution (undiluted) every 6 to 8 hours. Reported range: 2 to 20 mL of 10% solution (undiluted) every 2 to 6 hours.

20% solution: Inhalation: Usual dose: 3 to 5 mL of 20% solution (may be further diluted with sodium chloride or sterile water for inhalation) every 6 to 8 hours. Reported range: 1 to 10 mL of 20% solution (may be further diluted with sodium chloride or sterile water for inhalation) every 2 to 6 hours.

Tent, croupette: 10% or 20% solution: Dose must be individualized; dose is volume of solution necessary to maintain a very heavy mist in tent or croupette; in some cases, may require up to 300 mL solution/treatment.

Direct instillation: Infants, Children, and Adolescents:

Endotracheal: 1 to 2 mL of 10% to 20% solution every 1 to 4 hours as needed.

Percutaneous endotracheal catheter: 1 to 2 mL of 20% or 2 to 4 mL of 10% solution every 1 to 4 hours via syringe attached to catheter.

Diagnostic bronchogram

Diagnostic bronchogram: Infants, Children, and Adolescents: Nebulization or endotracheal: 1 to 2 mL of 20% solution or 2 to 4 mL of 10% solution administered 2 to 3 times prior to procedure.

Distal intestinal obstruction syndrome

Distal intestinal obstruction syndrome (previously known as meconium ileus equivalent): Limited data available; dosing regimens variable (polyethylene glycol has become more widely used for this indication):

Oral:

Children <10 years: 30 mL of 10% solution diluted in 30 mL juice or soda 3 times/day for 24 hours.

Children 10 years and Adolescents: 60 mL of 10% solution diluted in 60 mL juice or soda 3 times/day for 24 hours.

Note: Prior to treatment, administer a phosphosoda enema. A clear liquid diet should be used during the 24-hour acetylcysteine treatment.

Rectal enema: Children: Varying dosages; 100 to 300 mL of 4% to 6% solution 2 to 4 times daily; 50 mL of 20% solution 1 to 4 times daily and 5 to 30 mL of 10% to 20% solution 3 to 4 times daily have been used; rectal enemas appear to have less favorable results than oral administration (Ref). Note: Higher concentrations (10% to 20%) appear to increase fluid in the bowel and lead to increased incidence of adverse effects (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions (Significant): Considerations
Nonimmune anaphylaxis

Nonimmune anaphylaxis (previously known as anaphylactoid reactions) may occur, and symptoms include skin rash, flushing, urticaria, respiratory distress, bronchospasm, angioedema, and/or hypotension (Ref). Fatal reactions have been reported (Ref).

Mechanism: Dose-related; nonimmunogenic histamine release from mast cells and basophils (Ref). In contrast to IgE-mediated anaphylaxis, prior exposure to acetylcysteine is not required for development of symptoms; continued or future treatment is not contraindicated (Ref).

Onset: Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after initial exposure (Ref), and up to 24 hours in rare cases (Ref).

Risk factors:

Modifiable:

• Method of administration: Three-bag IV regimens result in more reactions than two-bag IV regimens (Ref)

• Rapid initial acetylcysteine infusion rate (Ref): Reducing the infusion rate has been shown to reduce the risk of nonimmune anaphylaxis (Ref)

Nonmodifiable:

• History of asthma (Ref)

• Lower acetaminophen concentrations (Ref): Patients with lower acetaminophen concentrations (<150 mg/L) may be at an increased risk for nonimmune anaphylaxis (Ref)

• Females (Ref)

• Age: Unknown. Younger age may result in increased (Ref) or decreased risk (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Intravenous: Reported adverse reactions are for infants, children, adolescents, and adults.

1% to 10%:

Cardiovascular: Edema (1% to 2%), facial flushing (≤8%), flushing (1% to 3%), tachycardia (3%)

Dermatologic: Pruritus (3% to 4%), skin rash (4%), urticaria (≤8%)

Gastrointestinal: Nausea (1%), vomiting (3% to 6%)

Hypersensitivity: Hypersensitivity reaction (1% to 7%; including severe hypersensitivity reaction)

Respiratory: Respiratory system disorder (2%; including bronchospasm, cough, dyspnea, respiratory distress, stridor, wheezing), rhonchi (1%), tightness in chest or throat (1%)

<1%:

Cardiovascular: Hypotension

Hypersensitivity: Anaphylaxis

Inhalation:

Frequency not defined:

Cardiovascular: Chest tightness

Dermatologic: Cold and clammy skin

Gastrointestinal: Nausea, stomatitis, vomiting

Nervous system: Drowsiness

Respiratory: Bronchoconstriction, bronchospasm, rhinorrhea

Miscellaneous: Fever

Postmarketing (any formulation):

Cardiovascular: Presyncope (Ref), syncope (Ref)

Hematologic & oncologic: Clotting factor suppression (Ref), increased INR (Ref)

Hypersensitivity: Angioedema (Ref), nonimmune anaphylaxis (Ref)

Nervous system: Anxiety (Ref)

Contraindications

Hypersensitivity to acetylcysteine or any component of the formulation.

Note: A prior nonimmune anaphylaxis (previously known as anaphylactoid) reaction is not a contraindication for administration of acetylcysteine during a subsequent acetaminophen overdose (Dart 2023).

Warnings/Precautions

Other warnings/precautions:

• Acute acetaminophen overdose: Appropriate use: Acetylcysteine is indicated in patients with a serum acetaminophen concentration that is on or above the treatment line when plotted on the revised Rumack-Matthew nomogram (Dart 2023). There are several situations where the nomogram is of limited use. Serum acetaminophen concentrations obtained <4 hours postingestion are not reliable, except to document the presence of acetaminophen (Seifert 2015). An undetectable acetaminophen concentration at 2 to 4 hours postingestion typically rules out signification ingestion; however, consultation with a poison center or clinical toxicologist is recommended to determine risk of acetaminophen toxicity (Dart 2023). Patients presenting late may have undetectable serum concentrations, despite having received a toxic dose. The nomogram is less predictive of hepatic injury following an acute overdose with an extended release acetaminophen product. The nomogram also does not take into account patients who may be at higher risk of acetaminophen toxicity (eg, patients with alcohol use disorder, malnourished patients, concurrent use of CYP2E1 enzyme-inducing agents [eg, isoniazid]). Nevertheless, acetylcysteine should be administered to any patient with signs of hepatotoxicity, even if the serum acetaminophen concentration is low or undetectable. Patients who present >24 hours after an acute ingestion or patients who present following an acute ingestion with an unknown or unreliable history may be candidates for acetylcysteine therapy; consultation with a poison center or clinical toxicologist is highly recommended.

• Repeated supratherapeutic ingestion (RSTI) of acetaminophen: Appropriate use: The Rumack-Matthew nomogram is not designed to be used following RSTIs. In general, an accurate past medical history, including a comprehensive acetaminophen ingestion history, in conjunction with serum transaminase concentrations and serum acetaminophen concentrations, may give the clinician insight as to the patient's risk of acetaminophen toxicity. Acetylcysteine is indicated when serum acetaminophen concentrations or serum acetaminophen concentrations are ≥20 mcg/mL, even in the absence of hepatic injury, or in patients with laboratory evidence and/or signs and symptoms of hepatotoxicity (Dart 2023; Hendrickson 2006; Jones 2000). Consultation with a poison center or a clinical toxicologist is highly recommended.

• Route of administration: Both oral and IV acetylcysteine are effective in reducing the risk of acetaminophen-related hepatotoxicity (Yarema 2009). A comprehensive review concurred that acetylcysteine therapy appears to reduce acetaminophen-related hepatotoxicity; however, it is also concluded that there is paucity of quality data to determine which route of administration or dosing regimen is superior (Chiew 2018). Consultation with a poison center or a clinical toxicologist is highly recommended to determine the preferred route and duration of administration.

Dosage form specific issues:

• Oral administration: Gastrointestinal hemorrhage: Oral administration of acetylcysteine may result in nausea and vomiting, which may exacerbate vomiting associated with acetaminophen overdose. Therefore, patients at risk of gastrointestinal hemorrhage (eg, esophageal varices, peptic ulcer) may experience an even higher risk of gastrointestinal hemorrhage during therapy.

• Inhalation: Since increased bronchial secretions may develop after inhalation, percussion, postural drainage, and suctioning should follow. If bronchospasm occurs, administer a bronchodilator; discontinue acetylcysteine if bronchospasm progresses.

• IV administration: IV administration can cause fluid overload, potentially resulting in hyponatremia, seizure, and death. Dilute before using.

Product Availability

Legubeti (acetylcysteine powder for oral solution): FDA approved February 2024; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Legubeti is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adult and pediatric patients. Consult the prescribing information for additional information.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Inhalation:

Generic: 10% [100 mg/mL] (4 mL, 10 mL, 30 mL); 20% [200 mg/mL] (4 mL, 10 mL, 30 mL)

Solution, Inhalation [preservative free]:

Generic: 10% [100 mg/mL] (4 mL, 10 mL, 30 mL); 20% [200 mg/mL] (4 mL, 10 mL, 30 mL)

Solution, Intravenous [preservative free]:

Acetadote: 200 mg/mL (30 mL)

Generic: 200 mg/mL (30 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Acetadote Intravenous)

200 mg/mL (per mL): $1.04

Solution (Acetylcysteine Inhalation)

10% (per mL): $3.26 - $4.37

20% (per mL): $1.30 - $4.79

Solution (Acetylcysteine Intravenous)

200 mg/mL (per mL): $1.11 - $4.40

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Inhalation:

Parvolex: 20% [200 mg/mL] ([DSC])

Generic: 20% [200 mg/mL] (10 mL, 30 mL)

Administration: Adult

Inhalation: Acetylcysteine is incompatible with tetracyclines, erythromycin, amphotericin B, iodized oil, chymotrypsin, trypsin, and hydrogen peroxide. Administer separately. Intermittent aerosol treatments are commonly given when patient arises, before meals, and just before retiring at bedtime.

Oral: Solution for oral administration: For the treatment of acetaminophen overdose, administer orally as a 5% solution. Use within 1 hour of preparation. The unpleasant odor (sulfur-like) becomes less noticeable as treatment progresses. If patient vomits within 1 hour of dose, readminister. (Note: It is helpful to put the acetylcysteine on ice, in a cup with a cover, and drink through a straw; alternatively, administer via an NG tube).

IV (Acetadote): Acetaminophen overdose: Note: It is critical that there is no delay in the administration of the loading dose or subsequent doses of acetylcysteine (Ref). Labeled regimens and a select alternative regimen are provided below; refer to institution-specific regimen where applicable.

“Three-bag regimen”:

Loading dose: Administer over 1 hour.

Second dose: Administer over 4 hours.

Third dose: Administer over 16 hours.

“Two-bag regimen”:

Loading dose: Administer over 4 hours.

Second dose: Administer over 16 hours.

If the commercial IV form is unavailable, the solution for inhalation has been used; each dose should be infused through a 0.2 micron Millipore filter (in-line) over 60 minutes (Ref); intravenous administration of the solution for inhalation is not USP 797-compliant.

Alternative recommendation (off label):

"Single-bag regimen" (off-label dosing): Administer initial dose (150 mg/kg) over 60 minutes, then decrease the rate and administer the remaining dose (14 mg/kg/hour) over 20 hours (Ref). Note: Patients weighing >69 kg will require a second bag to complete the dosing regimen.

Administration: Pediatric

Oral:

Solution for oral administration: Administer as a 5% solution (see Preparation for Administration); use within 1 hour of preparation. If patient vomits within 1 hour of dose, readminister. Note: The unpleasant odor (sulfur-like) becomes less noticeable as treatment progresses. It is helpful to put the acetylcysteine on ice, in a cup with a cover, and drink through a straw; alternatively, administer via an NG tube.

Parenteral:

IV: Acetadote:

Three-bag method: Neonates, Infants, Children, and Adolescents:

Loading dose: Administer IV over 60 minutes.

Second dose: Administer IV over 4 hours.

Third dose: Administer IV over 16 hours.

Note: If the commercial IV form is unavailable, the solution for inhalation has been used; each dose should be infused through a 0.2 micron Millipore filter (in-line) over 60 minutes (Ref); intravenous administration of the solution for inhalation is not USP 797-compliant.

Two-bag method: Infants, Children, and Adolescents (Ref):

First dose: Administer IV over 4 hours.

Second dose: Administer IV over 16 hours.

Inhalation: May be administered by nebulization; the 20% solution may be diluted with sodium chloride or sterile water for inhalation; the 10% solution may be used undiluted. Acetylcysteine solution for inhalation is incompatible with tetracyclines, erythromycin, amphotericin B, iodized oil, chymotrypsin, trypsin, and hydrogen peroxide. Administer separately.

Rectal: Inhalation solution may be given undiluted (10% to 20%) or diluted to 4% to 6% solution and administer rectally (Ref).

Use: Labeled Indications

Acetaminophen overdose: To prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSTI).

Mucolytic: Adjunct therapy in patients with abnormal, viscid, or inspissated mucous secretions in conditions such as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis, primary amyloidosis of the lung); acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); pulmonary complications of cystic fibrosis; tracheostomy care; pulmonary complications associated with surgery; use during anesthesia; posttraumatic chest conditions; atelectasis due to mucous obstruction; diagnostic bronchial studies (bronchograms, bronchospirometry, bronchial wedge catheterization).

Medication Safety Issues
Sound-alike/look-alike issues:

Acetylcysteine may be confused with acetylcholine

Mucomyst may be confused with Mucinex

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Charcoal, Activated: May decrease serum concentration of Acetylcysteine. Risk C: Monitor

Reproductive Considerations

A pregnancy test result should be documented when acetylcysteine is used as an antidote in patients who could become pregnant (Dart 2023).

Pregnancy Considerations

Acetylcysteine crosses the placenta.

Acetylcysteine may be used to treat acetaminophen overdose during pregnancy (Dart 2023; Wilkes 2005); IV administration may be preferred by some clinicians (Dart 2023). Delaying treatment to pregnant patients with acetaminophen toxicity may increase the risk of adverse maternal and fetal outcomes.

In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).

Breastfeeding Considerations

It is not known if acetylcysteine is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Based on pharmacokinetics, acetylcysteine should be nearly completely cleared 30 hours after administration; lactating patients may consider expressing and discarding breast milk for 30 hours after administration.

Monitoring Parameters

Acetaminophen overdose: Monitor patient for the development of anaphylaxis or nonimmune anaphylaxis (previously known as anaphylactoid reactions); monitor serum acetaminophen concentrations, AST, ALT, bilirubin, PT, INR, serum creatinine, BUN, serum glucose, hemoglobin, hematocrit, and electrolytes. Assess patient for nausea, vomiting, and skin rash following oral administration. Reassess LFTs for possible hepatotoxicity every 4 to 6 hours. An early elevation in the INR may be related to acetylcysteine therapy (Schmidt 2002). For the purpose of determining if discontinuation of acetylcysteine is appropriate, the serum acetaminophen concentration, serum transaminases, and PT/INR should be evaluated every 12 to 24 hours (Dart 2023).

Pregnancy test when used as an antidote in patients who could become pregnant (Dart 2023).

Mechanism of Action

Acetaminophen overdose: Acetylcysteine acts as a hepatoprotective agent by restoring hepatic glutathione, serving as a glutathione substitute, and enhancing the nontoxic sulfate conjugation of acetaminophen.

Mucolytic: Exerts mucolytic action through its free sulfhydryl group which opens up the disulfide bonds in the mucoproteins thus lowering mucous viscosity.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Inhalation: 5 to 10 minutes.

Duration: Inhalation: >1 hour.

Distribution: Vdss: 0.47 L/kg.

Protein binding: 66% to 87%.

Metabolism: Undergoes extensive first pass metabolism to form cysteine and disulfides (N,N-diacetylcysteine and N-acetylcysteine); cysteine is further metabolized to form glutathione and other metabolites.

Half-life elimination:

Reduced acetylcysteine: 2 hours.

Total acetylcysteine: Adults: 5.6 hours; Newborns: 11 hours.

Time to peak, plasma: Oral solution: 1 to 2 hours.

Excretion: Urine (13% to 38%).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Fluimucil;
  • (AR) Argentina: AC Lan | Acc | Acc expectorante | Acemuk | Acetilcisteina Teva | Broncolium | Maxvan;
  • (AT) Austria: Acetylcystein Aponova | Fluimucil Antidot | Nac akut;
  • (AU) Australia: Acetadote;
  • (BD) Bangladesh: Aceten | Mukof | Tylace;
  • (BE) Belgium: Acetylcysteine bexal | Acetylcysteine eg | Acetylcysteine eurogenerics | Acetylcysteine merck-generics | Acetylcysteine sandoz | Acetylcysteine teva generics belgium | Bisolaclar | Docacetyl | Lysomucil | Mucovics | Nactop | Touxium Mucolyticum;
  • (BF) Burkina Faso: Fluimucil | Mucomyst;
  • (BG) Bulgaria: Acc | Acc 200 | Fluimucil | Respifortin;
  • (BR) Brazil: Acetilcisteina | Fluicis | Fluimucil | Nac | Pulmonare;
  • (CH) Switzerland: Acc | Acc sandoz | Acemucol | Acetylcystein actavis | Acetylcystein Cimex | Acetylcystein Helvepharm | Acetylcystein klinge | Acetylcystein Teva | Acetylcystein zentiva | Acetylfelan | Amavita acetylcystein | Bexin hustenloeser | Coop vitality Acetylcystein | Dynamucil | Dynamucil 100 | Ecomucyl | Fluimucil | Fluimucil erkaeltungshusten | Fluimucil sugar | Helvetussin | Muco | Muco mepha | Muco X | Mucofluid | Mucomed | Mucosil acc | Mucostop | Neocitran hustenloeser | Secresol | Secresol ohne zucker | Solmucol | Solmucol Erkaeltungshusten | Sun store acetylcystein;
  • (CI) Côte d'Ivoire: Mucospire;
  • (CN) China: A si xin tai | Ao nuo feng | Fluimucil | Fu lou shi | Fu lu shi | Jin kang su li | Mucosof;
  • (CO) Colombia: Acemuk | Aflux | Evaflen | Fluimucil | Zifluvis;
  • (CZ) Czech Republic: Acc | Acc long | Acetylcystein max | Fluimucil | Nac al | Sanomux;
  • (DE) Germany: Acc | ACC akut | Acebraus | Acemuc | Acetylcystein | Acetylcystein Siga | Acetylcystein Trom | Acetyst | Atse | Azubronchin | Bromuc | Bronchowieb | Durabronchal | Fluimucil | Lindocetyl | Muciteran | Myxofat | Nac | Nac aiwa | Nac akut | Nac akut hustenloeser | Nac al | Nac Axcount | Nac stada | Phamuc | Pulmicret | Sigamucil | Siran akut | Stas akut hustenloesung | Tamuc | Temmlermucil | Tussamag Nac akut;
  • (DK) Denmark: Kuril | Mucolysin;
  • (DO) Dominican Republic: Acedip | Acypront | Flemaxin | Fluimucil | Mazenil;
  • (EC) Ecuador: Acemuk | Acetiflux | Acypront | Antusin | Drenaflen | Etimucil | Flemil | Flemisol | Flucil | Fluicetil s | Fluidine | Fluimexina | Fluimucil | Meinflu | N acetilcisteina | Virobron;
  • (EE) Estonia: Acc | Acetylcystein | Acetylcystein-stadapharm | Aceylcystein | Bronchostad | Granon | Mucovit | Nac | Sigamucil | Wintrozen;
  • (EG) Egypt: Acc | Fluimucil | Hidonac | Rotacysteine | Windy;
  • (ES) Spain: Acetilcisteina | Acetilcisteina acost | Acetilcisteina Alter | Acetilcisteina aristo | Acetilcisteina Bexalabs | Acetilcisteina davur | Acetilcisteina Kern pharma | Acetilcisteina MABO | Acetilcisteina sandoz | Acetilcisteina stada | Acetilcisteina Teva | Acetilcisteina ur | Bisolvon muco | Cinfamucol acetilcisteina | Fluimucil | Fluimucil forte | Flumil | Flumil Antidoto | Flumilexa | Frionex | Iniston mucus | Mucolibex | Ratiomucol | Sandozcare mucolitico;
  • (ET) Ethiopia: Acetylcisteine | Acetylcysteine sandoz;
  • (FI) Finland: Bisolaclar | Meditus | Mucomyst | Mucoporetta | Mucoratio;
  • (FR) France: Acetylcysteine alpex | Acetylcysteine Arrow | Acetylcysteine biogaran | Acetylcysteine merck | Acetylcysteine sandoz | Exomuc | Fluimucil | Hidonac | Mucodrill | Mucomyst;
  • (GB) United Kingdom: Acecil | Acepiro | Aceteff | Nacsys | Oronac;
  • (GR) Greece: Flumil Antidoto | Hidonac antidoto | Lilovon | Mucomyst | Trebon n | Vlenolys;
  • (HK) Hong Kong: Acypront | Advance mucolytic | Fluimucil | Fluimucil a | Hidonac | Nac;
  • (HR) Croatia: Fluimukan | Fluimukan akut | Fluimukan akut Junior | Fluimukan Long | Naxil forte;
  • (HU) Hungary: Acc | Acc/rg | Fluimucil | Fluimucil antidote | Mentopin;
  • (ID) Indonesia: Acetin | Fluimucil | Hidonac | L acys | Mukosil | Promucil | Resfar | Siran;
  • (IE) Ireland: Acetylcysteine Essential-Healthcare | Fluimucil | Nacsys;
  • (IL) Israel: Reolin | RHEUNAC | Siran;
  • (IN) India: Efetil | Effelyte | Effenac | Fibronac | Fiz nac | Flemonac | Fluimucil | Mucaryl | Muciace | Mucimega | Mucinac | Mucitec | Mucomelt | Mucomix | Mucosys | Mucotab et | Mucovisc | Mufost | Nacfil | Nacstene ef | Nacyres | Pulmofine nac | Quicnac | Ventirex evt | Viscojoy;
  • (IT) Italy: Acetilcisteina Angenerico | Acetilcisteina doc | Acetilcisteina eg | Acetilcisteina hexal | Acetilcisteina Mylan | Acetilcisteina pensa | Acetilcisteina ratiopharm | Acetilcisteina zentiva | Bisolmonus | Brocetil | Fluimucil | Fluimucil mucolitico | Fluimucil program san int | Frobemucil | Hidonac | N-acetilcisteina | Solmucol | Ultraflu;
  • (KE) Kenya: Trebon n;
  • (KR) Korea, Republic of: Br muco | Copuren | Ilyangbio acetylcysteine | Mirinol | Mucetine | Muteran | Pharmgen acetylcysteine | Sebron | Turant | Uvron | Yteran;
  • (KW) Kuwait: Acc;
  • (LB) Lebanon: Acc long | Fluimucil | Mukozero;
  • (LT) Lithuania: Acc | Acetylcystein stada | Fluimucil | Fluimucil Antidot | Mucanix | Muco | Nac | Respifortin | Wintrozen;
  • (LU) Luxembourg: Acc | Acetylcystein | Acetylcysteine sandoz | Bisolaclar | Lysomucil | Nac;
  • (LV) Latvia: Acc | Granon | Muco | Nac;
  • (MX) Mexico: Acc | Lysomucil | Mucomyst | Sensemoc;
  • (MY) Malaysia: Acetylcysteine sandoz | Fluimucil a | Hidonac | Infusol nac | Mentopin | Sanbeacetin | Stacytine | Stenac;
  • (NG) Nigeria: Acetylcysteine sandoz;
  • (NL) Netherlands: Acetylcysteine actavis | Acetylcysteine Birchwood | Acetylcysteine HTP | Acetylcysteine Imphos | Acetylcysteine m/g | Acetylcysteine Mdq | Acetylcysteine ratiopharm | Acetylcysteine RXT | Acetylcysteine Sanias | Bisolbruis | Etos hoest bruistabletten acetylcysteine | Fluimucil | Idyl hoest bruistabletten acetylcysteine | Livsane hoest bruistabletten acetylcysteine | MAE acetylcysteine | Pharcetil | San acetylcysteine | Vicks Hoest;
  • (NO) Norway: Acetylcystein | Acetylcystein sandoz | Bronkyl | Bronkyl forte | Granon | Mucomyst | Pharmanac;
  • (NZ) New Zealand: Acetadote | Nac ratiopharm;
  • (PE) Peru: Acemuk | Brimodin | Fluidasa | Fluimax | Fluimicar | Fluimucil | Flumikan | Mucocar;
  • (PH) Philippines: Acc | Acetimax | Dextein | Exflem | Fluimucil | Hidonac | Mucocystein | Pneumotyl;
  • (PL) Poland: Acc | Acc Max | Acc mini | Acc optima | Acetylcysteinum Flegamina | Acypront | Fluimucil | Fluimucil Antidot | Fluimucil forte | Muccosinal | Mucoatac | Nacecis;
  • (PR) Puerto Rico: Acetadote | Cetylev;
  • (PT) Portugal: Acetilcisteina Alter | Acetilcisteina azevedos | Acetilcisteina Bluepharma | Acetilcisteina Generis | Acetilcisteina Pharmakern | Acetilcisteina sandoz | Acetilcisteina Tolife | Acetilcisteina tussilene | Bisolvon efervescente | Cetussin | Exxelir | Fluimucil | Zentorant;
  • (PY) Paraguay: Broncolium;
  • (QA) Qatar: ACC | ACC Long | Alles | Asist Plus | Extal | Mucinac | Mucomyst | Mukozero | Nac Al | Parvolex;
  • (RO) Romania: Acc | Acetilcisteina rompharm | Acetilcisteina zentiva | Fluimucil | Hidonac | Mucofortin;
  • (RU) Russian Federation: Acc | Acc 100 | Acc long | Acestin | Acetylcystein | Acetylcystein hemofarm | Acetylcysteine teva | Fluimucil | N ac ratiopharm | Vicks active expectomed;
  • (SA) Saudi Arabia: Acc long | Acetylcistein;
  • (SE) Sweden: Acetylcystein Alternova | Acetylcystein astrazeneca | Acetylcystein meda | Acetylcystein Merck NM | Acetylcystein mint | Acetylcystein mylan | Acetylcystein NM Pharma | Acetylcystein sandoz | Mucomyst | Viskoferm;
  • (SG) Singapore: Fluimucil | Hidonac | Mentopin | Stenac;
  • (SI) Slovenia: Acibel | Fluimucil | Fluimukan | Hidonac antidoto;
  • (SK) Slovakia: Acc | Acc injekt | Acc long | Acetylcystein dr.max | Fluimucil | Mucofortin | Sanomux;
  • (SR) Suriname: Acetylcysteine alpex | Acetylcysteine apotex | Da hoestbruistabletten acetylcysteine | Idyl hoest bruistabletten acetylcysteine | Livsane hoest bruistabletten acetylcysteine;
  • (TH) Thailand: Acetin | Cystaline | Enumine nac | Flemex ac | Fluimucil | Fluimucil a | Hidonac | Iraxil | Mysoven | Nac | Nac long | Stenac;
  • (TN) Tunisia: Fluimucil;
  • (TR) Turkey: Acetylcystein | Alles | Astein | Bronpax | Cinetix | Extal | Mentopin | Mucomax | Muconex | Muconex fort | Mucoplus | Mukozero | Nac;
  • (TW) Taiwan: Acc | Acetin | Acetyl | Acetyleine | Chitan | Cystenon | Detoxnac | Encore | Flucil | Fluimucil a | Flutafin | Fumucil | Mucocil | Mucopd | Sistin | Stacytine | Stenac | Tanson;
  • (UA) Ukraine: Ac help | Acc | Acc long | Acetal soluble | Acetin | Acetylcystein | Asibrox | Dvace long | Dvatse | Fluimucil | Multigrip broncho | Sanorin-broncho;
  • (VE) Venezuela, Bolivarian Republic of: Acemuk | Pulmolix | Zifluvis;
  • (VN) Viet Nam: Abbsin | Suresh | Tufsine;
  • (ZA) South Africa: Acc | Amuco | Mucatak | Muco acyst | Mucofizz | Mucotrin | Pholtex mucus | Trinflem | Tussmuco;
  • (ZM) Zambia: Acc
  1. Acetadote (acetylcysteine) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; November 2024.
  2. Acetylcysteine injection [prescribing information]. Lake Forest, IL: Akorn, Inc; October 2014.
  3. Acetylcysteine solution (inhalation or oral) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; May 2023.
  4. Acetylcysteine solution (inhalation or oral) [product monograph]. Mississauga, Ontario, Canada: Hikma Canada Limited; June 2022.
  5. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT). Circulation. 2011;124(11):1250-1259. doi:10.1161/CIRCULATIONAHA.111.038943 [PubMed 21859972]
  6. Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344-e426. doi:10.1161/CIR.0000000000000134 [PubMed 25249585]
  7. Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: Caution in patients with asthma. Emerg Med J. 2002;19(6):594-595. doi:10.1136/emj.19.6.594 [PubMed 12421803]
  8. Aw MM, Dhawan A, Baker AJ, Mieli-Vergani G. Neonatal paracetamol poisoning. Arch Dis Child Fetal Neonatal Ed. 1999;81(1):F78. doi:10.1136/fn.81.1.f77c [PubMed 10744435]
  9. Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med. 1998;31(6):710-715. doi: 10.1016/s0196-0644(98)70229-x [PubMed 9624310]
  10. Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res A Clin Mol Teratol. 2003;67(2):133-140. doi: 10.1002/bdra.10007 [PubMed 12769509]
  11. Bailey GP, Najafi J, Elamin ME, et al. Delays during the administration of acetylcysteine for the treatment of paracetamol overdose. Br J Clin Pharmacol. 2016;82(5):1358-1363. doi:10.1111/bcp.13063 [PubMed 27412926]
  12. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41(12):2114-2118. doi:10.1016/s0735-1097(03)00487-x [PubMed 12821233]
  13. Bateman DN, Dear JW. Acetylcysteine in paracetamol poisoning: a perspective of 45 years of use. Toxicol Res (Camb). 2019;8(4):489-498. doi:10.1039/c9tx00002j [PubMed 31341611]
  14. Bebarta VS, Kao L, Froberg B, et al. A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. Clin Toxicol (Phila). 2010;48(5):424-430. doi:10.3109/15563650.2010.486381 [PubMed 20524832]
  15. Betten DP, Burner EE, Thomas SC, Tomaszewski C, Clark RF. A retrospective evaluation of shortened-duration oral N-acetylcysteine for the treatment of acetaminophen poisoning. J Med Toxicol. 2009;5(4):183-190. doi:10.1007/BF03178264 [PubMed 19876849]
  16. Betten DP, Cantrell FL, Thomas SC, Williams SR, Clark RF. A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning. Ann Emerg Med. 2007;50(3):272-279. doi:10.1016/j.annemergmed.2006.11.010 [PubMed 17210206]
  17. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  18. Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10):1211-1217. doi:10.1161/CIRCULATIONAHA.106.687152 [PubMed 17309916]
  19. Bucaretchi F, Fernandes CB, Branco MM, et al. Acute liver failure in a term neonate after repeated paracetamol administration. Rev Paul Pediatr. 2014;32(1):144-148. doi:10.1590/s0103-05822014000100021 [PubMed 24676202]
  20. Chiew AL, Page CB, Clancy D, Mostafa A, Roberts MS, Isbister GK. 2-Methyl-4-chlorophenoxyacetic acid (MCPA) and bromoxynil herbicide ingestion. Clin Toxicol (Phila). 2018;56(5):377-380. doi:10.1080/15563650.2017.1385790 [PubMed 28988498]
  21. Chiew AL, Reith D, Pomerleau A, et al. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust. 2020;212(4):175-183. doi:10.5694/mja2.50428 [PubMed 31786822]
  22. Coulson J, Thompson JP. Paracetamol (acetaminophen) attenuates in vitro mast cell and peripheral blood mononucleocyte cell histamine release induced by N-acetylcysteine. Clin Toxicol (Phila). 2010;48(2):111-4. doi:10.3109/15563650903520959 [PubMed 20136478]
  23. Daoud A, Dalhoff KP, Christensen MB, Bøgevig S, Petersen TS. Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine. Clin Toxicol (Phila). 2020;58(7):698-704. doi:10.1080/15563650.2019.1675886 [PubMed 31601129]
  24. Dart RC, Erdman AR, Olson KR, et al; American Association of Poison Control Centers. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(1):1-18. doi:10.1080/15563650500394571 [PubMed 16496488]
  25. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  26. Dart RC, Mullins ME, Matoushek T, et al. Management of acetaminophen poisoning in the US and Canada: a consensus statement. JAMA Netw Open. 2023;6(8):e2327739. doi:10.1001/jamanetworkopen.2023.27739 [PubMed 37552484]
  27. de la Pintiére A, Beuchée A, Bétrémieux PE. Intravenous propacetamol overdose in a term newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88(4):F351-352. doi:10.1136/fn.88.4.f351-b [PubMed 12819181]
  28. Douglas D, Smilkstein M. Deferoxamine-iron induced pulmonary injury and N-acetylcysteine. J Toxicol Clin Toxicol. 1995;33(5):495.
  29. Epperson LC, Weiss ST, Cao DJ. A case report of a severe, unusually delayed anaphylactoid reaction to intravenous N-acetylcysteine during treatment of acute acetaminophen toxicity in an adolescent. J Med Toxicol. 2021;17(1):75-79. doi:10.1007/s13181-020-00804-5 [PubMed 32821982]
  30. European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222-1261. doi:10.1016/j.jhep.2019.02.014 [PubMed 30926241]
  31. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  32. Falk JL. Oral N-acetylcysteine given intravenously for acetaminophen overdose: we shouldn't have to, but we must. Crit Care Med. 1998;26(1):7. doi:10.1097/00003246-199801000-00005 [PubMed 9428532]
  33. Ghannoum M, Kazim S, Grunbaum AM, Villeneuve E, Gosselin S. Massive acetaminophen overdose: effect of hemodialysis on acetaminophen and acetylcysteine kinetics. Clin Toxicol (Phila). 2016;54(6):519-522. doi:10.1080/15563650.2016.1175006 [PubMed 27118496]
  34. Gosselin S, Juurlink DN, Kielstein JT, et al. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2014;52(8):856-867. doi:10.3109/15563650.2014.946994 [PubMed 25133498]
  35. Hanly JG, Fitzgerald MX. Meconium ileus equivalent in older patients with cystic fibrosis. Br Med J (Clin Res Ed). 1983;286(6375):1411-1413. doi:10.1136/bmj.286.6375.1411 [PubMed 6404483]
  36. Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990;335(8705):1572-1573. doi:10.1016/0140-6736(90)91388-q [PubMed 1972496]
  37. Hendrickson RG, Bizovi KE. Acetaminophen. In Goldfrank's Toxicologic Emergencies, 8th edition. Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds. New York: The McGraw-Hill Companies, Inc; 2006:523-543.
  38. Hernandez SH, Howland M, Schiano TD, Hoffman RS. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Clin Toxicol (Phila). 2015;53(10):941-949. doi:10.3109/15563650.2015.1100305 [PubMed 26484583]
  39. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20(2):123-134. doi:10.2165/00003088-199120020-00004 [PubMed 2029805]
  40. Isbister GK, Bucens IK, Whyte IM. Paracetamol overdose in a preterm neonate. Arch Dis Child Fetal Neonatal Ed. 2001;85(1):F70-F72. doi:10.1136/fn.85.1.f70 [PubMed 11420329]
  41. Isbister GK, Downes MA, Mcnamara K, Berling I, Whyte IM, Page CB. A prospective observational study of a novel 2-phase infusion protocol for the administration of acetylcysteine in paracetamol poisoning. Clin Toxicol (Phila). 2016;54(2):120-126. doi:10.3109/15563650.2015.1115057 [PubMed 26691690]
  42. Johnson MT, McCammon CA, Mullins ME, Halcomb SE. Evaluation of a simplified N-acetylcysteine dosing regimen for the treatment of acetaminophen toxicity. Ann Pharmacother. 2011;45(6):713-720. doi:10.1345/aph.1P613. [PubMed 21586653]
  43. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol. 1998;36(4):277-285. doi:10.3109/15563659809028022 [PubMed 9711192]
  44. Jones AL. Recent advances in the management of late paracetamol poisoning. Emerg Med. 2000;12(1):14-21.
  45. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289(5):553-558. doi:10.1001/jama.289.5.553 [PubMed 12578487]
  46. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991;303(6809):1026-1029. doi:10.1136/bmj.303.6809.1026 [PubMed 1954453]
  47. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(suppl 1):1-138. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf. Accessed January 9, 2018.
  48. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006 [PubMed 34895950]
  49. Legubeti (acetylcysteine) [prescribing information]. Humacao, Puerto Rico: Galephar Pharmaceutical Research Inc; February 2024.
  50. Lyon ME, Lyon AW. N-Acetylcysteine interference with a glucose dehydrogenase linked glucose meter. J Diabetes Sci Technol. 2022;16(5):1114-1119. doi:10.1177/1932296821999416 [PubMed 33719602]
  51. Mascarenhas MR. Treatment of gastrointestinal problems in cystic fibrosis. Curr Treat Options Gastroenterol. 2003;6(5):427-441. doi:10.1007/s11938-003-0045-2 [PubMed 12954149]
  52. McNulty R, Lim JME, Chandru P, Gunja N. Fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose. Clin Toxicol (Phila). 2018;56(7):618-621. doi:10.1080/15563650.2017.1408812 [PubMed 29219630]
  53. Mohammed S, Jamal AZ, Robison LR. Serum sickness-like illness associated with N-acetylcysteine therapy. Ann Pharmacother. 1994;28(2):285. doi:10.1177/106002809402800230 [PubMed 8173157]
  54. Mokhlesi B, Leikin JB, Murray P, Corbridge TC. Adult toxicology in critical care: Part II: specific poisonings. Chest. 2003;123(3):897-922. doi:10.1378/chest.123.3.897 [PubMed 12628894]
  55. Nevin DG, Shung J. Intravenous paracetamol overdose in a preterm infant during anesthesia. Paediatr Anaesth. 2010;20(1):105-107. doi:10.1111/j.1460-9592.2009.03210.x [PubMed 20078803]
  56. Nolin TD, Ouseph R, Himmelfarb J, McMenamin ME, Ward RA. Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2010;5(9):1588-1594. doi:10.2215/CJN.00210110 [PubMed 20538838]
  57. Pakravan N, Waring WS, Sharma S, Ludlam C, Megson I, Bateman DN. Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose. Clin Toxicol (Phila). 2008;46(8):697-702. doi:10.1080/15563650802245497 [PubMed 18803085]
  58. Pavlek L, Kraft M, Simmons C, et al. Acetaminophen and acetylsalicylic acid exposure in a preterm infant after maternal overdose. Am J Perinatol. 2019;36(2):136-140. doi:10.1055/s-0038-1661405 [PubMed 29945281]
  59. Perman J, Breslow L, Ingal D. Nonoperative treatment of meconium ileus equivalent. Am J Dis Child. 1975;129(10):1210-1211. doi:10.1001/archpedi.1975.02120470056016 [PubMed 1190145]
  60. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol. 1989;37(5):501-506. doi:10.1007/BF00558131 [PubMed 2598989]
  61. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2(6198):1097-1100. doi:10.1136/bmj.2.6198.1097 [PubMed 519312]
  62. Rashid ST, Salman M, Myint F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40(6):1136-1141. doi:10.1016/j.jvs.2004.09.026 [PubMed 15622367]
  63. Refer to manufacturer's labeling.
  64. Rodgers G, Matyunas N, Ross M, et al. Sulfhemoglobinemia associated with N-acetylcysteine (NAC) therapy of acetaminophen (APAP) overdose: A Case Report. Clin Toxicol. 1995;33(5):530.
  65. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2023;46(10):e151-e199. doi:10.2337/dci23-0036 [PubMed 37471273]
  66. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila). 2009;47(2):81-88. doi:10.1080/15563650802665587 [PubMed 19280424]
  67. Schmidt LE. Identification of patients at risk of anaphylactoid reactions to N-acetylcysteine in the treatment of paracetamol overdose. Clin Toxicol (Phila). 2013;51(6):467-72. doi:10.3109/15563650.2013.799677 [PubMed 23697458]
  68. Schmidt LE, Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol. 2001;51(1):87-91. doi:10.1046/j.1365-2125.2001.01305.x [PubMed 11167669]
  69. Schmidt LE, Knudsen TT, Dalhoff K, Bendtsen F. Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. Lancet. 2002;360(9340):1151-1152. doi:10.1016/S0140-6736(02)11194-9 [PubMed 12387966]
  70. Seifert SA, Kirschner RI, Martin TG, Schrader RM, Karowski K, Anaradian PC. Acetaminophen concentrations prior to 4 hours of ingestion: impact on diagnostic decision-making and treatment. Clin Toxicol. 2015;53(7):618-623. doi:10.3109/15563650.2015.1059942 [PubMed 26107627]
  71. Sivilotti ML, Juurlink DN, Garland JS, et al. Antidote removal during haemodialysis for massive acetaminophen overdose. Clin Toxicol (Phila). 2013;51(9):855-863. doi:10.3109/15563650.2013.844824 [PubMed 24134534]
  72. Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med. 1991;20(10):1058-1063. doi:10.1016/s0196-0644(05)81352-6 [PubMed 1928874]
  73. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557-1562. doi:10.1056/NEJM198812153192401 [PubMed 3059186]
  74. Soldini D, Zwahlen H, Gabutti L, Marzo A, Marone C. Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. Eur J Clin Pharmacol. 2005;60(12):859-864. doi:10.1007/s00228-004-0850-0 [PubMed 15657783]
  75. Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med. 2016;164(6):406-416. doi:10.7326/M15-1456. [PubMed 26830221]
  76. Sudanagunta S, Camarena-Michel A, Pennington S, Leonard J, Hoyte C, Wang GS. Comparison of two-bag versus three-bag N-acetylcysteine regimens for pediatric acetaminophen toxicity. Ann Pharmacother. 2023;57(1):36-43. doi:10.1177/10600280221097700 [PubMed 35587124]
  77. Syafira N, Graudins A, Yarema M, Wong A. Comparing development of liver injury using the two versus three bag acetylcysteine regimen despite early treatment in paracetamol overdose. Clin Toxicol (Phila). 2022;60(4):478-485. doi:10.1080/15563650.2021.1998518 [PubMed 34758680]
  78. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-184. doi:10.1056/NEJM200007203430304 [PubMed 10900277]
  79. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  80. Walls L, Baker CF, Sarkar S. Acetaminophen-induced hepatic failure with encephalopathy in a newborn. J Perinatol. 2007;27(2):133-135. doi:10.1038/sj.jp.7211641 [PubMed 17262050]
  81. Waring WS, Stephen AF, Robinson OD, Dow MA, Pettie JM. Lower incidence of anaphylactoid reactions to N-acetylcysteine in patients with high acetaminophen concentrations after overdose. Clin Toxicol (Phila). 2008;46(6):496-500. doi:10.1080/15563650701864760 [PubMed 18584360]
  82. Weisbord SD, Gallagher M, Jneid H, et al; PRESERVE Trial Group. Outcomes after angiograph with sodium bicarbonate and acetylcysteine. N Engl J Med. 2017. doi:10.1056/NEJMoa1710933 [PubMed 29130810]
  83. Wilkes JM, Clark LE, Herrera JL. Acetaminophen overdose in pregnancy. South Med J. 2005;98(11):1118-1122. doi:10.1097/01.smj.0000184792.15407.51 [PubMed 16351032]
  84. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619. doi:10.1093/eurheartj/ehu278. [PubMed 25173339]
  85. Wolf SJ, Heard K, Sloan EP, Jagoda AS; American College of Emergency Physicians. Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose. Ann Emerg Med. 2007;50(3):292-313. doi:10.1016/j.annemergmed.2007.06.014 [PubMed 17709050]
  86. Wong A. Comment: comparison of 2-bag versus 3-bag N-acetylcysteine regimens for pediatric acetaminophen toxicity. Ann Pharmacother. 2023;57(4):505. doi:10.1177/10600280221117323 [PubMed 35950557]
  87. Wong A, Graudins A. N-acetylcysteine regimens for paracetamol overdose: time for a change? Emerg Med Australas. 2016a;28(6):749-751. doi:10.1111/1742-6723.12610 [PubMed 27193944]
  88. Wong A, Graudins A. Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. Clin Toxicol (Phila). 2016b;54(2):115-119. doi:10.3109/15563650.2015.1115055 [PubMed 26594846]
  89. Wong A, Isbister G, McNulty R, et al. Efficacy of a two bag acetylcysteine regimen to treat paracetamol overdose (2NAC study). EClinicalMedicine. 2020;20:100288. doi:10.1016/j.eclinm.2020.100288 [PubMed 32211597]
  90. Woo OF, Anderson IB, Kim SY, et al. Shorter duration of N-acetylcysteine (NAC) for acute acetaminophen poisoning. Clin Toxicol. 1995;33(5):508.
  91. Woo OF, Mueller PD, Olson KR, Anderson IB, Kim SY. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med. 2000;35(4):363-368. [PubMed 10736123]
  92. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(suppl 1):1S-39S. doi:10.1378/chest.125.1_suppl.1s [PubMed 14734689]
  93. Yarema M, Chopra P, Sivilotti MLA, et al. Anaphylactoid reactions to intravenous N-acetylcysteine during treatment for acetaminophen poisoning. J Med Toxicol. 2018;14(2):120-127. doi:10.1007/s13181-018-0653-9 [PubMed 29423816]
  94. Yarema MC, Johnson DW, Berlin RJ, et al. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med. 2009;54(4):606-614. doi:10.1016/j.annemergmed.2009.05.010 [PubMed 19556028]
  95. Yip L, Dart RC, Hurlbut KM. Intravenous administration of oral N-acetylcysteine. Crit Care Med. 1998;26(1):40-43. doi:10.1097/00003246-199801000-00014 [PubMed 9428541]
  96. Zyoud SH, Awang R, Syed Sulaiman SA, Sweileh WM, Al-Jabi SW. Incidence of adverse drug reactions induced by N-acetylcysteine in patients with acetaminophen overdose. Hum Exp Toxicol. 2010;29(3):153-160. doi:10.1177/0960327109359642 [PubMed 20071472]
  97. Zyoud SH, Awang R, Sulaiman SA, Al-Jabi SW. N-acetylcysteine-induced headache in hospitalized patients with acute acetaminophen overdose. Fundam Clin Pharmacol. 2011;25(3):405-410. doi:10.1111/j.1472-8206.2010.00831.x [PubMed 20584210]
Topic 9317 Version 375.0